Ambrx Biopharma EBITDA 2020-2021 | AMAM

Ambrx Biopharma ebitda from 2020 to 2021. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Ambrx Biopharma Annual EBITDA
(Millions of US $)
2021 $-62
2020 $-11
2019 $-20
Ambrx Biopharma Quarterly EBITDA
(Millions of US $)
2021-12-31 $7
2020-12-31
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.110B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.407B 10.06
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.180B 16.07
Biohaven Pharmaceutical Holding (BHVN) United States $10.170B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.223B 0.00
Arcus Biosciences (RCUS) United States $1.792B 45.42
Emergent Biosolutions (EBS) United States $1.625B 6.95
Myovant Sciences (MYOV) United Kingdom $1.313B 0.00
Zymeworks (ZYME) Canada $0.365B 0.00
Gelesis Holdings (GLS) United States $0.122B 0.00
Enzo Biochem (ENZ) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00